Spadin
unknown riskAlso: TREK-1 antagonist · Propeptide PE4
Spadin is a naturally occurring peptide derived from the sortilin propeptide that acts as an antagonist of TREK-1 potassium channels. Demonstrates rapid antidepressant effects in animal models (within days vs. weeks for SSRIs). Novel mechanism of action with no current human trials.
Reported Benefits
Antidepressant
Mice: rapid antidepressant-like behavior within 4 days — faster onset than SSRIs. No human data.
Mechanism of Action
Antagonizes TREK-1 (TWIK-related K+ channel 1); increases serotonergic and noradrenergic tone; hippocampal neurogenesis increase in animal models.
Rapid Onset: The Key Claim
The major pharmaceutical problem with current antidepressants is 2–6 week onset to effect. Spadin animal data shows behavioral improvement within 4 days via a completely different mechanism (K+ channel blockade). If this translates to humans, it could address a significant unmet need.
Human trials are the critical missing piece.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Unknown in humans
Contraindications
- •Insufficient data
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Spadin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →